Stelara (ustekinumab) / J&J, Tanabe Pharma, BMS - LARVOL DELTA

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis. (PubMed, JAMA Dermatol) - "Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ciltacabtagene Autoleucel Immune Effector Cell Enteritis/Colitis Is Driven By Persistent Clonal CAR+ T-Cells. (TCT-ASTCT-CIBMTR 2026) - "Another patient treated with infliximab and then ustekinumab had initial improvement with relapse. Post-cilta-cel IEC-EC is a rare complication with high morbidity and mortality. We present the largest single institution cohort of post-cilta-cel IEC-EC to date, demonstrating frequent presence of clonal CAR+ T-cell populations associated with these cases and responses to a single dose of cyclophosphamide monotherapy. Impacted patients had increased CAR persistence."

IO biomarker • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • CD4 • CD8

Randomized Phase II Trial of Ustekinumab for GVHD Prevention in Matched Unrelated Donor Transplants: Primary Trial Results (TCT-ASTCT-CIBMTR 2026) - P2 | "GVHD prevention included standard tacrolimus/methotrexate GVHD prophylaxis together with either Ustekinumab (IV induction dose 4-72 hours prior to start of HCT conditioning; then subcutaneous injection on days 50; 100 and 160 post-HCT) or matched placebo. Review primary trial results from novel GVHD prevention trial 3. Interpret results; with attention to overall results and conditioning regimen-specific subgroups"

Clinical • P2 data • Acute Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • IL12A • IL23A

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Therapeutic sequencing strategies and identification of difficult to treat cases in inflammatory bowel disease at a referral center in Mexico (ECCO-IBD 2026) - "First-line therapy consisted mainly of adalimumab and infliximab (33.5% each), followed by vedolizumab (23.5%) and ustekinumab (5.9%). Conclusion Therapeutic sequencing in IBD patients revealed complex clinical trajectories, with a subgroup fulfilling criteria for difficult-to-treat disease. Progressive reduction in treatment persistence with each subsequent line was observed, suggesting increased clinical refractoriness and highlighting the need for timely optimization of therapeutic decision making."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

Corticosteroid use during maintenance is associated with decreased persistence of advanced therapies in Ulcerative Colitis but not in Crohn’s Disease (ECCO-IBD 2026) - "Corticosteroid use in UC was associated with reduced persistence of tumour necrosis factor inhibitor (TNFi) (median 20.0 vs 23.0 months, HR=1.09 [95%CI: 1.01-1.18], P =0.027), vedolizumab (25.0 vs 54.0, HR=1.51 [95%CI: 1.36-1.69], P 8 months, HR=2.47 [95%CI: 1.02-5.95], P =0.036). This highlights that corticosteroid-requiring flares may signal the need to change AT. In contrast, corticosteroid use did not affect ustekinumab or vedolizumab in CD and was associated with increased TNFi persistence in CD, suggesting the potential for salvage with dose optimisation and/or combination therapy."

Clinical • Metastases • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Clinical and endoscopic improvement of pediatric pouchitis with ustekinumab. (PubMed, Pediatr Int) - No abstract available

Journal • Gastrointestinal Disorder • Inflammation • Pediatrics

Analysis of 2020–2024 prescription trends of adalimumab for crohn’s disease in Brazil (ECCO-IBD 2026) - "This downward trend likely reflects diversification toward newer biologics and small-molecule agents such as vedolizumab, ustekinumab, and upadacitinib (7–10). Despite limitations inherent to administrative data, consistent reductions across analytical models support a nationwide shift in Crohn’s disease management. Continued monitoring incorporating clinical outcomes and patient-level registries remains vital to sustain equitable, evidence-based biologic access within the SUS framework (18–20)."

Crohn's disease • Immunology • Inflammatory Bowel Disease

Preventing UTIs in Women with IBD: Early Results of a Randomized Double-Blind Trial of D-Mannose (ECCO-IBD 2026) - "Biologic therapies included 6 infliximab, 4 adalimumab, 4 ustekinumab, and 11 vedolizumab. Conclusion These preliminary findings suggest that D-mannose prophylaxis may significantly reduce UTI incidence in women with IBD, particularly for E. coli infections, while demonstrating optimal safety and compatibility with biologic treatment. The study is ongoing, and final results will clarify the preventive role of D-mannose in this high-risk population."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Real world evidence of ustekinumab on health-related quality of life in patients with Crohn’s disease: A prospective nationwide K-STAR study in Korea (ECCO-IBD 2026) - "Conclusion This study demonstrated ustekinumab showed sustained improvements in HRQoL over one year in Korean patients with CD. Early treatment with ustekinumab in bio-naïve CD patients can be helpful in enhancing quality of life for CD patients."

Clinical • HEOR • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

Safety and Efficacy of Ustekinumab in Indian Patients with Moderate to Severe Crohn’s Disease: A Multicentre, Interventional, Phase IV study (ECCO-IBD 2026) - "Conclusion The study findings showed that UST was well tolerated and effective in Indian pts with moderate to severe CD, consistent with the existing global evidence. No new safety signals, including tuberculosis, were identified"

Clinical • P4 data • Crohn's disease • Immunology • Inflammatory Bowel Disease • CRP

Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. (PubMed, Ann Gastroenterol) - "The randomized controlled trials (RCTs) included evaluated ustekinumab, mirikizumab, risankizumab, and guselkumab. Risankizumab was most effective in induction, while guselkumab was more effective in maintenance. Head-to-head trials are warranted."

Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • IL23A

Multi-omics biomarkers for predicting treatment response in inflammatory bowel disease (ECCO-IBD 2026) - "Methods A multi-omics analysis was performed, integrating transcriptomics, proteomics, metabolomics, and metagenomic across intestinal tissue, serum, urine, serum-derived extracellular vesicles (EVs), and stool from 130 IBD patients treated with anti-TNFα, ustekinumab, vedolizumab, or tofacitinib (Figure 1). Integration of multi-omics layers provided complementary insights, emphasizing the central role of the intestinal microenvironment and host-microbiota interactions in mediating treatment outcomes. Conclusion These findings establish a comprehensive framework for precision therapy in IBD, identifying predictive biomarkers with translational potential to optimize personalized therapy, minimize ineffective treatment, and reduce disease burden."

Biomarker • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Real-world Outcomes of Ustekinumab, Vedolizumab, and Tumor Necrosis Factor Inhibitors in Very Early Onset Inflammatory Bowel Disease: A Multicentre Cohort Study (ECCO-IBD 2026) - "Although VEO-IBD often presents as severe, treatment-resistant disease requiring biologic agents, studies comparing effectiveness between biologics like infliximab (IFX), adalimumab (ADL), ustekinumab (UST) and vedolizumab (VDZ) remain limited. No discontinuations due to infusion reactions or other adverse events occurred with UST or VDZ. Conclusion UST and VDZ were effective and well tolerated even when used as second-line or subsequent therapies for VEO-IBD."

Clinical • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

JAK inhibitors versus anti-IL12/23 agents as third-line therapy in refractory Ulcerative Colitis: an international multi-centre study (3D-UC) (ECCO-IBD 2026) - "In practice, vedolizumab 2 , JAK inhibitors(JAKi) 3 , and IL-12/23 inhibitors are used sequentially 4 , with IL-12/23 or JAKi often reserved for third-line therapy 4...Patients were treated with mirikizumab, ustekinumab, upadacitinib, filgotinib and tofacitinib...In the anti-IL12/23 cohort, 1 patient developed infectious endocarditis, while 2 cases of lymphoma and basal cell carcinoma were reported among JAKi. Conclusion JAKi demonstrated superior clinical response rates at week 12 as third line therapy versus anti-IL12/23, with upadacitinib achieving higher, but not statistically significant, remission rates."

Clinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A

Mirikizumab, guselkumab, and risankizumab did not differ in remission efficacy adjusting for imbalanced treatment discontinuation in network meta-analysis of treat-through trials for Crohn’s disease (ECCO-IBD 2026) - "Background Traditional Crohn’s disease (CD) trials used a re-randomisation design, but more recent trials, including trials with the interleukin (IL)-23p19 inhibitors mirikizumab, guselkumab, and risankizumab, used a treat-through design vs a direct comparator ustekinumab; however, there were clinically relevant different trial settings. Consistent results were observed across adjusted approaches compared to the unadjusted NMA. No difference in remission efficacy was observed across mirikizumab, guselkumab, and risankizumab."

Retrospective data • Crohn's disease • Immunology • Inflammatory Bowel Disease

A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence. (PubMed, Am J Case Rep) - "The patient experienced response failure to infliximab and adalimumab, despite both agents being maintained within the therapeutic range...He was started on ustekinumab, which was stopped after 9 months due to active endoscopic disease...At 9 months, his repeat colonoscopy showed quiescent disease, with a Simple Endoscopic Score for Crohn's disease score <4. CONCLUSIONS This report supports recent regulatory approvals, reports, and study findings that have shown the effectiveness of upadacitinib and risankizumab as second-line therapy in patients with refractory inflammatory bowel disease."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Real-world effectiveness and safety of mirikizumab in refractory, biologic-experienced ulcerative colitis patients (ECCO-IBD 2026) - "Clinical remission rates were similar regardless of prior ustekinumab exposure (26.9% vs 26.5%), number of prior biologics (26.3% vs 26.7%), or prior anti-TNF therapy (22.2% vs 27.0%), with no significant differences. Conclusion Mirikizumab is an effective and safe therapeutic option for biologic-experienced UC patients, showing short- and mid-term efficacy. The reduced response in JAK inhibitor-exposed patients highlights the potential importance of treatment sequencing in refractory disease."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Dose escalation in participants with primary/secondary loss of response to conventional dosing of ustekinumab in paediatric Crohn’s Disease (UNITI Jr study) (ECCO-IBD 2026) - P3 | "Q4W dosing resulted in higher serum concentrations that were within the exposure range observed in adult CD ustekinumab studies. The safety profile of ustekinumab in these participants was similar to that in the overall UNITI Jr study and the known profile in adults."

Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

Gender-based differences in clinical outcomes among Crohn’s disease patients treated with ustekinumab: a retrospective cohort study (ECCO-IBD 2026) - "However, females demonstrated lower rates of intestinal obstruction but higher rates of diarrhea and abdominal pain compared to males. These findings suggest potential gender-related variations in clinical presentation and response that may warrant tailored management strategies."

Clinical data • Retrospective data • Crohn's disease • Immunology • Inflammatory Bowel Disease

Effectiveness and safety of mirikizumab in ulcerative colitis: real-world data from the Latium net (ECCO-IBD 2026) - "The early clinical response was sustained over time, and SFCR rates improved with continued therapy. Comparable outcomes in biologic-experienced patients, together with trends related to prior ustekinumab exposure and extended induction, support the therapeutic utility of mirikizumab across diverse clinical scenarios."

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Rapid enhancement of Quality of Life after ustekinumab initiation in patients with Ulcerative Colitis: Results from a prospective study using the SIBDQ-9 (ECCO-IBD 2026) - "Conclusion Treatment with UST was associated with a rapid and sustained improvement in quality of life as measured by the SIBDQ-9, with progressive increases from baseline to week 16. Patients achieving clinical remission reported significantly higher quality-of-life scores, while no differences were observed according to FC normalization."

Clinical • HEOR • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Sequencing Patterns and Efficacy of Biological Therapies and Small Molecules in Patients with Ulcerative Colitis: A Single-Center Retrospective Study (ECCO-IBD 2026) - "Patients underwent 78 courses of advanced therapy (Infliximab 30, Adalimumab 11, Golimumab 8, Vedolizumab 22, Ustekinumab 1, Tofacitinib 2, Filgotinib 2, Ozanimod 2). Conclusion Advanced biologic and small-molecule therapies were effective and generally well-tolerated in patients with refractory UC. Infliximab showed the most durable first-line treatment response, whereas Adalimumab was associated with a shorter treatment duration."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Perianal Lesion Index as a Predictor of Advanced Therapy Maintenance in Perianal Crohn's Disease (ECCO-IBD 2026) - "AT included infliximab (IFX, n=17), adalimumab (ADA, n=5), ustekinumab (UST, n=17), vedolizumab (VDZ, n=7), upadacitinib (n=2), risankizumab (n=1). Early intervention before disease progression may improve outcomes, though further validation is warranted. Regular PLI assessment warrants consideration for incorporation into clinical practice."

Clinical • Metastases • Crohn's disease • Immunology • Inflammatory Bowel Disease